{"id":10071,"date":"2026-03-23T08:22:10","date_gmt":"2026-03-23T13:22:10","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10071"},"modified":"2026-03-23T08:24:28","modified_gmt":"2026-03-23T13:24:28","slug":"nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/","title":{"rendered":"Nanoscope Therapeutics anuncia la publicaci\u00f3n de un nuevo estudio que destaca la evaluaci\u00f3n de la visi\u00f3n funcional en enfermedades de la retina."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

DALLAS<\/span>, 23 de marzo de 2026<\/span> \u2014 Nanoscope Therapeutics, Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy la publicaci\u00f3n de su \u00faltimo estudio observacional revisado por pares en una revista de Springer Nature, Documenta Oftalmol\u00f3gica<\/i>, advancing the field’s understanding of how to measure meaningful vision improvements in patients with severe vision loss in the real world.<\/p>\n

El estudio subraya la necesidad cr\u00edtica de realizar pruebas en pacientes que sufren p\u00e9rdida de visi\u00f3n debido a la p\u00e9rdida de las funciones de los bastones y los conos, destacando las herramientas que capturan con precisi\u00f3n las mejoras funcionales y la experiencia del paciente, y que pueden utilizarse en los flujos de trabajo est\u00e1ndar de retina.<\/p>\n

“While best-corrected visual acuity (BCVA) has long been the gold standard in ophthalmology, it can be supplemented with new ways to assess how patients with severe vision loss navigate their daily lives,” said Samarendra Mohanty, Ph.D., the senior author and Chief Scientific Officer at Nanoscope Therapeutics, “I’m proud that our peer-reviewed findings can help clinicians and treating physicians feel confident in using these tests to assess their patients’ functional vision.”<\/p>\n

The publication highlights findings from a prospective, observational study in 35 subjects, 25 with severe vision loss due to retinitis pigmentosa (RP) and 10 with normal vision. This study provides supportive evidence for the reliability and validity of the Multi-luminance Shape Discrimination Test (MLSDT) as a performance-based assessment of visual ability in individuals with severe visual impairment. In addition to assessing BCVA in the primary endpoint, the RESTORE Ph2b\/3 clinical trial of Nanoscope’s lead therapy, MCO-010, assessed patients’ functional vision using MLSDT in a secondary endpoint. At Week 52, the majority of MCO-010-treated patients improved by 2 or more luminance levels in MLSDT, a clinically meaningful magnitude. MCO-010 is the first therapy to demonstrate clinically meaningful and statistically significant improvements in vision in patients with RP having severe vision loss in a randomized, sham-controlled, registrational trial.<\/p>\n

Samuel Barone, M.D., Chief Medical Officer at Nanoscope Therapeutics added, “While Nanoscope continues to lead through its development of ground-breaking optogenetic therapies, this observational study shows our commitment to partnering with the retina community on how therapeutic success is measured.”<\/p>\n

Los resultados del estudio est\u00e1n disponibles en l\u00ednea en Springer Nature. aqu\u00ed<\/a>.<\/p>\n

Acerca de la plataforma MCO
<\/b>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p>\n

Acerca de Nanoscope Therapeutics
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (NCT04945772<\/a>), se est\u00e1 llevando a cabo una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de convertirse en el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar una Ensayo de registro de fase 3<\/a> en 2026. MCO-010 ha recibido las designaciones de V\u00eda R\u00e1pida y Medicamento Hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de EMA de Medicamento Hu\u00e9rfano para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. MCO-010 tambi\u00e9n ha recibido las designaciones de Sakigake (Pionero) y Medicamento Hu\u00e9rfano en Jap\u00f3n por parte del MHLW. Tambi\u00e9n se espera que un programa de Fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience en 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p>\n

Contacto:
<\/b>Nanoscope Therapeutics, Inc
(817) 857-1186
PR@nanostherapeutics.co<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS, March 23, 2026 — Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced the publication of its latest peer-reviewed observational study in a Springer Nature journal, Documenta Ophthalmologica, advancing the field’s understanding of how to measure meaningful vision improvements […]<\/p>\n","protected":false},"author":1,"featured_media":10072,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10071","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T13:22:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-23T13:24:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease\",\"datePublished\":\"2026-03-23T13:22:10+00:00\",\"dateModified\":\"2026-03-23T13:24:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/\"},\"wordCount\":650,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MLSD-Publication_REV2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/\",\"name\":\"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MLSD-Publication_REV2.jpg\",\"datePublished\":\"2026-03-23T13:22:10+00:00\",\"dateModified\":\"2026-03-23T13:24:28+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MLSD-Publication_REV2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MLSD-Publication_REV2.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia la publicaci\u00f3n de un nuevo estudio que destaca la evaluaci\u00f3n de la visi\u00f3n funcional en enfermedades de la retina - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-03-23T13:22:10+00:00","article_modified_time":"2026-03-23T13:24:28+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease","datePublished":"2026-03-23T13:22:10+00:00","dateModified":"2026-03-23T13:24:28+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/"},"wordCount":650,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MLSD-Publication_REV2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/","url":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/","name":"Nanoscope Therapeutics anuncia la publicaci\u00f3n de un nuevo estudio que destaca la evaluaci\u00f3n de la visi\u00f3n funcional en enfermedades de la retina - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MLSD-Publication_REV2.jpg","datePublished":"2026-03-23T13:22:10+00:00","dateModified":"2026-03-23T13:24:28+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MLSD-Publication_REV2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MLSD-Publication_REV2.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10071"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10071\/revisions"}],"predecessor-version":[{"id":10076,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10071\/revisions\/10076"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10072"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}